Last reviewed · How we verify

NCT05242107

Omega-3 on Lipid Profile and Serum Leptin Level n Neonates With Intrauterine Growth Restriction

Completed NA Last updated 16 February 2022
What this trial tests

NA trial testing Omega-3 supplement group in Lipid Profile in 70 participants. Completed in 10 January 2022.

Timeline
1 June 2021
Primary endpoint
1 January 2022
10 January 2022

Quick facts

Lead sponsorTanta University
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment70
Start date1 June 2021
Primary completion1 January 2022
Estimated completion10 January 2022
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Tanta University

Who can join

Adults 1 Day to 4 Weeks, any sex, with Lipid Profile or Neonates. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of our study will demonstrate the effect of omega 3 supplementation on serum lipid profile level and leptin level in neonates with Intrauterine Growth Restriction( IUGR)

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Lipid profile after omega-3 supplementation in neonates with intrauterine growth retardation: a randomized controlled trial.
    Elsheikh M, El Amrousy D, El-Mahdy H, Dawoud H, et al · · 2023 · cited 2× · PMID 37202530 · DOI 10.1038/s41390-023-02632-z

Verify or expand the search:

Other recruiting trials for Lipid Profile

Currently open trials in the same condition.

Other Tanta University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05242107.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing